SCHEMBL13856554

SCHEMBL13856554

CCOC(=O)C1=C(C)N=c2s/c(=C\c3ccc(-c4ccc(C(=O)O)cc4)o3)c(=O)n2C1c1ccc(C)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.66
KMT2A Q03164 6/20 0.66
PTGES O14684 1/20 0.63
NR1H4 Q96RI1 1/20 0.61
PTPN22 Q9Y2R2 4/20 0.57
DUSP3 P51452 4/20 0.57
PTPN1 P18031 1/20 0.57
PPM1A P35813 1/20 0.57
PTPN9 P43378 1/20 0.57
PTPN5 P54829 1/20 0.57
PTPN18 Q99952 1/20 0.57
PTPN11 Q06124 1/20 0.56
POLB P06746 4/20 0.54
NPSR1 Q6W5P4 3/20 0.54
BLM P54132 3/20 0.54
L3MBTL1 Q9Y468 3/20 0.54
ALDH1A1 P00352 2/20 0.54
MAPT P10636 2/20 0.54
USP2 O75604 1/20 0.54
PKM P14618 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13856501 0.95 PTGES (0.68) MEN1KMT2APTGESNR1H4PTPN22
SCHEMBL13856650 0.93 MEN1 (0.64) MEN1KMT2APTGESNR1H4PTPN22
SCHEMBL13856447 0.93 PTPN22 (0.68) MEN1KMT2APTGESNR1H4PTPN22
SCHEMBL13856613 0.91 PTGES (0.64) MEN1KMT2APTGESNR1H4PTPN22
SCHEMBL13856499 0.91 PTGES (0.67) MEN1KMT2APTGESNR1H4PTPN22
SCHEMBL12325905 0.90 NPSR1 (0.69) MEN1KMT2APTGESNR1H4PTPN22
SCHEMBL13856782 0.90 MEN1 (0.63) MEN1KMT2APTGESNR1H4PTPN22
SCHEMBL14922048 0.89 MEN1 (0.68) MEN1KMT2APTGESNR1H4PTPN22
SCHEMBL13856510 0.89 NPSR1 (0.64) MEN1KMT2APTGESNR1H4PTPN22
SCHEMBL13856592 0.88 PTPN22 (0.61) MEN1KMT2APTGESNR1H4PTPN22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131401-A1 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. (US) 2009-05-21 US disclosed
US-20090131401-A1 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. (US) 2009-05-21 US disclosed
US-7405235-B2 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed
US-7405235-B2 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131401-A1 Transcription factor modulating compounds and methods of use thereof JUN, CREBBP, TFEB MEN1 4225/4885KMT2A 806/4885PTGES 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.